Animal models in which nintedanib has demonstrated antifibrotic effects
| Trigger | Model |
| Chemical | Bleomycin-induced lung fibrosis [73, 75, 76] |
| Environmental | Silica-induced lung fibrosis [73] |
| Allergic | Ovalbumin-induced lung fibrosis and remodelling [77] |
| Vascular | Fra-2 transgenic mice (model of systemic sclerosis) [69] |
| Immunological | SKG transgenic mice+zymosan (model of RA-ILD) [78] |
RA-ILD: rheumatoid arthritis-associated interstitial lung disease.